Sana Biotechnology Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Sana Biotechnology sono diminuiti a un tasso annuo medio di -3.2%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 19%.

Informazioni chiave

-3.2%

Tasso di crescita degli utili

82.4%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-72.1%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16

Ripartizione dei ricavi e delle spese

Come Sana Biotechnology guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:SANA Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	-245	73	223
31 Mar 24	-309	73	281
31 Dec 23	-283	73	254
30 Sep 23	-276	76	246
30 Jun 23	-362	63	284
31 Mar 23	-320	61	248
31 Dec 22	-269	58	204
30 Sep 22	-300	56	232
30 Jun 22	-298	54	232
31 Mar 22	-207	53	135
31 Dec 21	-356	50	275
30 Sep 21	-358	47	266
30 Jun 21	-327	41	230
31 Mar 21	-433	34	336
31 Dec 20	-285	28	232
30 Sep 20	-215	25	174
31 Dec 19	-131	22	102

Guadagni di qualità: SANA al momento non è redditizia.

Margine di profitto in crescita: SANA al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: SANA non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 3.2% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di SANA nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: SANA non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -2.3% ).

Rendimento del capitale proprio

ROE elevato: SANA ha un Return on Equity negativo ( -72.1% ), in quanto al momento non è redditizio.

Sana Biotechnology Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Price target decreased to US$9.75

High number of new directors

Price target decreased to US$11.75

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

High number of new directors

Sana Biotechnology A Buy For Potential Cancer Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Growth Index

Sana Biotechnology, Inc. Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology, Inc. Plan to Relocate Manufacturing to Bothell

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington

Price target decreased to US$12.50

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology, Inc. to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Price target decreased to US$18.00

High number of new directors

Independent Director recently bought US$204k worth of stock

Price target decreased to US$23.67

Sana Biotechnology: Exciting Preclinical Science

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Executive VP notifies of intention to sell stock

Independent Director Geoffrey von Maltzahn has left the company

Senior VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology: Hypoimmune Cell Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 1000 Value Index

Sana Biotechnology reports Q1 results

Sana Biotechnology to Present Pre-Clinical Data At American Society of Gene & Cell Therapy Annual Meeting 2021

Sana Biotechnology, Inc. has completed an IPO in the amount of $587.5 million.

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate